معرفی
Dr. Tom Peat is an Adjunct Professor at the University of New South Wales (UNSW) within the School of Biotechnology and Biomolecular Sciences. With a strong background in molecular biophysics and structural biology, he has made significant contributions to protein crystallography and structure-based drug development.
- BA in biophysics and biochemistry from University of California at Berkeley
- Masters and PhD from Columbia University in Molecular Biophysics
Dr. Peat's research spans structural biology, protein engineering, and drug discovery, with a particular focus on fragment-based screening approaches. His work has significant implications for cancer therapeutics, enzyme mechanisms, and structural enzymology. He has contributed over 300 structures to the Protein Data Bank and has been actively involved in fragment screening technologies for structure-based drug development. Two of the projects he has been involved with have progressed into phase 2 clinical trials for cancer treatments.
Analysis of his recent publications (2020-2024) reveals a consistent research trajectory in structural biology with applications in drug discovery. His work frequently involves protein crystallography to understand enzyme mechanisms, particularly related to carbonic anhydrases, cancer targets, and biocatalysts. The publications demonstrate expertise in fragment-based drug discovery, structure-activity relationships, and applying structural insights to therapeutic development, especially in oncology.
Dr. Peat has founded two biotechnology companies in Australia and has been involved with early-stage biotech companies in the US, demonstrating his ability to translate academic research into commercial applications. His collaborations span multiple institutions and research groups, reflecting the interdisciplinary nature of modern structural biology and drug discovery.
His laboratory work appears to focus on protein structure-function relationships, with particular emphasis on enzyme mechanisms relevant to drug development. The extensive publication record indicates active research programs in structural biology with applications to cancer therapeutics, enzyme engineering, and biocatalysis.